TGFbeta type II-type III receptor fusions
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Nov 8, 2022
Grant Date -
N/A
app pub date -
Apr 4, 2019
filing date -
Mar 28, 2012
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
Certain embodiments are directed to novel heterotrimeric fusions in which the ectodomain of the TGF-β type II receptor (TβP?II) is coupled to the N- and C-terminal ends of the endoglin-domain of the TGF-β type III receptor (TpRIIIE). Certain embodiments are directed to novel heterotrimeric polypeptides in which the ectodomain of the TGF-β type II receptor (TI3RII) is coupled to the N- and C-terminal ends of the endoglin-domain (E domain) of the TGF-β type III receptor (TI3RIII). This trimeric receptor, known as RER, can bind all three TGF-β isoforms with sub-nanomolar affinity and is effective at neutralizing signaling induced by all three TGF-β isoforms, but not other ligands of the TGF-β superfamily, such as activins, growth and differentiation factors (GDFs), and bone morphonogenetic proteins (BMPs).
First Claim
Other Claims data not available
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
- 0 Citation Count
- C12N Class
- 0 % this patent is cited more than
- 3 Age
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 3.5 Year Payment | $1600.00 | $800.00 | $400.00 | May 8, 2026 |
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | May 8, 2030 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | May 8, 2034 |